title: Oral immunotherapy for the treatment of peanut allergy: is it ready for prime time?
authors.affiliation: Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: rwood@jhmi.edu.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Wood
authors.affiliation: Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
authors.forename: Hugh A
authors.initials: HA
authors.lastname: Sampson
mesh_terms: D000322:Adrenergic Agonists / Q000627:therapeutic use*; D000485:Allergens / Q000008:administration & dosage*; D000707:Anaphylaxis / Q000188:drug therapy*; D010367:Arachis / Q000009:adverse effects*; D003888:Desensitization, Immunologic / Q000379:methods*; D004837:Epinephrine / Q000627:therapeutic use*; D006801:Humans; D021183:Peanut Hypersensitivity / Q000628:therapy*; D010940:Plant Proteins / Q000008:administration & dosage*
chemical_list: D000322:Adrenergic Agonists; D000485:Allergens; D010940:Plant Proteins; D004837:Epinephrine